What is OpenEvidence?
OpenEvidence is an artificial intelligence platform designed for doctors and healthcare professionals. Think of it as a powerful AI copilot that synthesizes vast amounts of medical knowledge—from prestigious journals like The New England Journal of Medicine
and JAMA to clinical guidelines—into quick, reliable answers for questions that arise at the point of care. Founded in 2022 by Daniel Nadler, the platform has seen rapid adoption, with reports that over 65% of U.S. physicians use it monthly. Its core function is to help clinicians make high-stakes decisions by providing evidence-based insights in seconds, covering everything from treatment options and drug interactions to the latest research findings.
Closing the Information Gap
For medical professionals in many parts of the world, subscribing to dozens of expensive medical journals is simply not feasible. This creates a significant information gap, where clinicians may struggle to keep up with the latest evidence-based practices. The internet has helped, but cost and accessibility remain major barriers. OpenEvidence's new initiative, launched in partnership with the AI company Anthropic, directly targets this problem. By offering its platform for free to doctors in approximately 100 low- and middle-income countries—including nations like Uganda, Haiti, and Mongolia—the company aims to democratize access to critical medical knowledge. The goal, as stated by founder Daniel Nadler, is to ensure that "access to medical knowledge shouldn't depend on geography."
A Mission with a Business Model
Providing a high-tech platform to thousands of users for free raises an obvious question: how is it sustainable? OpenEvidence's business model is built on a 'freemium' approach. While access for individual clinicians in the U.S., Europe, and now these 100 target countries is free, the company generates revenue primarily through highly targeted advertising from pharmaceutical and medical device companies on its platform. This strategy allowed OpenEvidence to bypass slow procurement cycles at hospitals and grow rapidly among individual doctors. By building a massive user base—U.S. clinicians reportedly used the platform 42 million times in August 2026 alone—the company created valuable ad inventory, funding its mission to provide free access elsewhere.
Adapting AI for Global Health
A major concern with deploying AI systems globally is that models trained on data from high-income countries may not be relevant in regions with different disease patterns, resources, and treatment availability. OpenEvidence and Anthropic are addressing this by creating locally adapted versions of the tool. Anthropic provides the back-end AI technology, while OpenEvidence is responsible for making the system "context adaptive." The company has been working with health organizations in Rwanda and Botswana to tailor the platform, with local doctors and nurses testing the tool and providing feedback. This work ensures the AI accounts for the realities on the ground, a critical step for making the information genuinely useful and avoiding the pitfalls of one-size-fits-all tech solutions.
The Road Ahead
While the initiative is a significant step forward, challenges remain. Effective implementation requires more than just providing access; it involves training, governance, and ensuring accountability. However, the potential impact is enormous. Even in places where clinics may lack consistent electricity, most doctors have smartphones, which can now become a gateway to world-class medical information. This project highlights a growing trend of leveraging technology to tackle global health disparities. As Anthropic's president, Daniela Amodei, noted, market incentives alone would not have made this happen, highlighting the role of philanthropically-minded efforts in advancing global health equity.
